Most prescription drugs manufactured overseas—are they safe?

September 10, 2012

Most pharmaceutical drugs in Canada are manufactured overseas in countries such as India, China and others, yet how can we be confident the drug supply is safe, writes a drug policy researcher in an opinion piece in CMAJ (Canadian Medical Association Journal).

Alarmed by alerts about potentially harmful products such as nonprescription erectile dysfunction drugs with names like Uprizing 2.0 and Ying Da Wang—most from overseas—Alan Cassels began to think about sold in Canada. Are they safe? Who regulates them?

"Most Canadians probably don't know that many of our pharmaceuticals come from places like India and China," writes Cassels. "How often do our regulators dust off their passports and fly to China or India to ensure that the plants producing pharmaceuticals are clean, follow proper manufacturing techniques and contain what is on the label (and nothing else)?"

He was unable to find out much from Health Canada because information about inspections is not public.

"This situation doesn't leave me with the warm fuzzies," he writes. "Especially when we're dealing with—how can I say this nicely—a federal agency that refuses to even enforce the laws against illegal on a bus shelter at the end of my street?"

Explore further: CMAJ calls on federal government to protect Canadians from unsafe drugs

More information: www.cmaj.ca/lookup/doi/10.1503/cmaj.120416

Related Stories

CMAJ calls on federal government to protect Canadians from unsafe drugs

April 18, 2011
Canada needs to modernize its pharmaceutical drug laws to ensure that new drugs as well as older drugs are safe for Canadians, states an editorial in CMAJ (Canadian Medical Association Journal).

Safe prescribing information for children in Canada often hard to find

June 13, 2011
Accurate, safe prescribing information for children is often unavailable to doctors in Canada because pharmaceutical companies will not disclose information to Health Canada, states an editorial in CMAJ (Canadian Medical ...

Canadians should demand commitments for pharmacare program, says CMAJ

April 26, 2011
Canada needs a national pharmacare program and federal leaders must commit adequate funding, states an editorial in CMAJ (Canadian Medical Association Journal).

Female feticide in Canada requires action

January 16, 2012
Canada should prohibit disclosure of the sex of a fetus until after 30 weeks of pregnancy to combat female feticide which is practised by some ethnic groups in Canada and the United States, states an editorial in CMAJ (Canadian ...

Pharmaceutical intellectual property laws need reform

November 7, 2011
Canada's pharmaceutical intellectual property laws need major reform to encourage and protect innovation in developing new drugs, states an analysis in CMAJ (Canadian Medical Association Journal).

Recommended for you

Cancer drugs' high prices not justified by cost of development, study contends

September 12, 2017
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs.

Non-psychotropic cannabinoids show promise for pain relief

September 4, 2017
Some cancers love bone. They thrive in its nutrient-rich environment while gnawing away at the very substrate that sustains them, all the while releasing inflammatory substances that cause pain—pain so severe that opioids ...

Fentanyl drives rise in opioid-linked deaths in U.S.

August 31, 2017
(HealthDay)—Fentanyl, a synthetic narcotic, is a key player in America's continuing epidemic of opioid-related overdose deaths, two new studies report.

Eating triggers endorphin release in the brain

August 28, 2017
Finnish researchers have revealed how eating stimulates brain's endogenous opioid system to signal pleasure and satiety.

Cholesterol-lowering drugs may fight infectious disease

August 21, 2017
That statin you've been taking to lower your risk of heart attack or stroke may one day pull double duty, providing protection against a whole host of infectious diseases, including typhoid fever, chlamydia, and malaria.

Data revealed under FOI shows benefits of multiple sclerosis drug currently blocked by regulators

August 17, 2017
A drug that is blocked by the EU regulatory system has now been found to improve the quality of life of people with multiple sclerosis (MS), according to a study by Queen Mary University of London (QMUL).

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.